FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381158051> ?p ?o ?g. }

• W4381158051 abstract "Abstract Background Tyrosine kinase inhibitors combined with conventional chemotherapy (CC) in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) has achieved promising efficacy and safety outcomes. The study was conducted to compare the cost-effectiveness between imatinib (HANSOH Pharma, Jiangsu, China) and dasatinib (CHIATAI TIANQING Pharma, Jiangsu, China) in treating pediatric Ph-positive ALL when combined with CC from the perspective of the health system in China. Methods A Markov model was established to simulate a hypothetical cohort of pediatric Ph-positive ALL patients receiving imatinib or dasatinib, combined with CC. The model was designed using a 10-year horizon, a 3- month cycle, and a 5% discount rate. Three health states were included: alive with progression-free survival, progressed disease, and death. Patient characteristics and transition probabilities were estimated based on clinical trials. Other relevant data, such as direct treatment costs and health utility data were extracted from published literature and Sichuan Province’s centralized procurement and supervision platform. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the results. The willingness-to-pay (WTP) was set as three times China’s GDP per capita in 2021. Results In the base-case analysis, the total medical costs were $89,701 and $101,182, and the quality-adjusted life years (QALYs) gained were 1.99 and 2.70, for imatinib and dasatinib regimens, respectively. The incremental cost-effectiveness ratio for dasatinib versus imatinib was $16,170/QALY. The probabilistic sensitivity analysis indicated that treatment with dasatinib combined with CC achieved a 96.4% probability of cost-effectiveness at a WTP threshold of $37,765/QALY. Conclusions Dasatinib combined with CC is likely to be a cost-effective strategy compared to imatinib combination therapy for pediatric Ph-positive ALL in China at a WTP threshold of $37,765/QALY." @default.
• W4381158051 created "2023-06-20" @default.
• W4381158051 creator A5001877165 @default.
• W4381158051 creator A5004658590 @default.
• W4381158051 creator A5008533731 @default.
• W4381158051 creator A5008923915 @default.
• W4381158051 creator A5012718640 @default.
• W4381158051 creator A5053979421 @default.
• W4381158051 creator A5089435742 @default.
• W4381158051 date "2023-06-19" @default.
• W4381158051 modified "2023-10-17" @default.
• W4381158051 title "Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China" @default.
• W4381158051 cites W1510901763 @default.
• W4381158051 cites W1965507024 @default.
• W4381158051 cites W1982967337 @default.
• W4381158051 cites W1994309500 @default.
• W4381158051 cites W2064831267 @default.
• W4381158051 cites W2070209092 @default.
• W4381158051 cites W2091403456 @default.
• W4381158051 cites W2093296595 @default.
• W4381158051 cites W2096336184 @default.
• W4381158051 cites W2114947413 @default.
• W4381158051 cites W2126499930 @default.
• W4381158051 cites W2127226843 @default.
• W4381158051 cites W2314704099 @default.
• W4381158051 cites W2413232426 @default.
• W4381158051 cites W2737446049 @default.
• W4381158051 cites W2792717768 @default.
• W4381158051 cites W2806544610 @default.
• W4381158051 cites W2889761439 @default.
• W4381158051 cites W2901346202 @default.
• W4381158051 cites W2936533408 @default.
• W4381158051 cites W2936766192 @default.
• W4381158051 cites W2963381164 @default.
• W4381158051 cites W2999407263 @default.
• W4381158051 cites W3000081737 @default.
• W4381158051 cites W3124264152 @default.
• W4381158051 cites W3132994416 @default.
• W4381158051 cites W3153404280 @default.
• W4381158051 cites W3206806235 @default.
• W4381158051 cites W4206608028 @default.
• W4381158051 cites W4231828794 @default.
• W4381158051 cites W4312218439 @default.
• W4381158051 cites W4312705269 @default.
• W4381158051 doi "https://doi.org/10.1186/s12913-023-09600-7" @default.
• W4381158051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37331932" @default.
• W4381158051 hasPublicationYear "2023" @default.
• W4381158051 type Work @default.
• W4381158051 citedByCount "1" @default.
• W4381158051 crossrefType "journal-article" @default.
• W4381158051 hasAuthorship W4381158051A5001877165 @default.
• W4381158051 hasAuthorship W4381158051A5004658590 @default.
• W4381158051 hasAuthorship W4381158051A5008533731 @default.
• W4381158051 hasAuthorship W4381158051A5008923915 @default.
• W4381158051 hasAuthorship W4381158051A5012718640 @default.
• W4381158051 hasAuthorship W4381158051A5053979421 @default.
• W4381158051 hasAuthorship W4381158051A5089435742 @default.
• W4381158051 hasBestOaLocation W43811580511 @default.
• W4381158051 hasConcept C112930515 @default.
• W4381158051 hasConcept C126322002 @default.
• W4381158051 hasConcept C143998085 @default.
• W4381158051 hasConcept C187212893 @default.
• W4381158051 hasConcept C2777583451 @default.
• W4381158051 hasConcept C2778729363 @default.
• W4381158051 hasConcept C2779536868 @default.
• W4381158051 hasConcept C3019080777 @default.
• W4381158051 hasConcept C515549039 @default.
• W4381158051 hasConcept C71924100 @default.
• W4381158051 hasConceptScore W4381158051C112930515 @default.
• W4381158051 hasConceptScore W4381158051C126322002 @default.
• W4381158051 hasConceptScore W4381158051C143998085 @default.
• W4381158051 hasConceptScore W4381158051C187212893 @default.
• W4381158051 hasConceptScore W4381158051C2777583451 @default.
• W4381158051 hasConceptScore W4381158051C2778729363 @default.
• W4381158051 hasConceptScore W4381158051C2779536868 @default.
• W4381158051 hasConceptScore W4381158051C3019080777 @default.
• W4381158051 hasConceptScore W4381158051C515549039 @default.
• W4381158051 hasConceptScore W4381158051C71924100 @default.
• W4381158051 hasIssue "1" @default.
• W4381158051 hasLocation W43811580511 @default.
• W4381158051 hasLocation W43811580512 @default.
• W4381158051 hasLocation W43811580513 @default.
• W4381158051 hasOpenAccess W4381158051 @default.
• W4381158051 hasPrimaryLocation W43811580511 @default.
• W4381158051 hasRelatedWork W1881846856 @default.
• W4381158051 hasRelatedWork W1983852790 @default.
• W4381158051 hasRelatedWork W1993369250 @default.
• W4381158051 hasRelatedWork W2092828011 @default.
• W4381158051 hasRelatedWork W2097799776 @default.
• W4381158051 hasRelatedWork W2184534421 @default.
• W4381158051 hasRelatedWork W2314058894 @default.
• W4381158051 hasRelatedWork W2618548116 @default.
• W4381158051 hasRelatedWork W2941817612 @default.
• W4381158051 hasRelatedWork W4253096022 @default.
• W4381158051 hasVolume "23" @default.
• W4381158051 isParatext "false" @default.
• W4381158051 isRetracted "false" @default.
• W4381158051 workType "article" @default.